Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects

Elizabeth Hyland, Tim Mant, Pantelis Vlachos, Neil Attkins, Martin Ullmann, Sanjeev Roy, Volker Wagner, Elizabeth Hyland, Tim Mant, Pantelis Vlachos, Neil Attkins, Martin Ullmann, Sanjeev Roy, Volker Wagner

Abstract

Aims: The aim of the study was to compare the pharmacokinetics (PK), safety and tolerability of the proposed adalimumab biosimilar MSB11022 (Merck) with Humira(®) (AbbVie), sourced from both the US (US reference product [US-RP]) and Europe (European reference medicinal product [EU-RMP]).

Methods: In this phase 1 double-blind, parallel group trial (EMR200588-001), 213 healthy volunteers were randomized 1 : 1 : 1 to receive a single dose (40 mg) of MSB11022, US-RP or EU-RMP in order to achieve 80% power assuming a 5% difference among groups and a 10% dropout rate. Following a preplanned blinded sample size re-assessment after more than 50% of the originally planned subjects had been observed, the sample size was increased to 237 (79 per arm) to ensure 213 completers. Primary PK endpoints analyzed by non-compartmental methods, were area under the curve (AUC) from time 0 extrapolated to infinity (AUC(0,∞)), maximum observed concentration (Cmax ), and AUC from time 0 to the last quantifiable concentration (AUC(0,tlast )). PK equivalence was declared if the 90% CI for the test : reference ratio lay within the 80-125% equivalence margin. Bioequivalence was demonstrated if all three PK parameters met the PK equivalence criteria. Safety and tolerability were also evaluated.

Results: Mean serum concentration-time profiles for the three treatments were similar. MSB11022 demonstrated PK equivalence to US-RP and EU-RMP for all primary endpoints. The geometric means of AUC(0,∞), Cmax and AUC(0,tlast ) following a single dose of MSB11022 were 2276.05 μg ml(-1) h, 3.44 μg ml(-1) and 1983.90 μg ml(-1) h, respectively. Adverse events (AEs) were similar across all groups, with treatment-emergent AEs (TEAEs) reported by 62.8%, 56.3% and 62.0% of subjects within the MSB11022, US-RP and EU-RMP groups, respectively. Most of the TEAEs were considered mild and unrelated to study drug. No deaths or severe AEs related to the study drug were reported.

Conclusions: Bioequivalence between MSB11022, US-RP and EU-RMP was demonstrated. Safety, tolerability and immunogenicity profiles were similar between subjects receiving MSB11022 and US-RP or EU-RMP. These data support the further clinical evaluation of MSB11022 as a proposed biosimilar of adalimumab.

Keywords: adalimumab; biosimilar; pharmacokinetics; safety.

© 2016 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society.

Figures

Figure 1
Figure 1
Subject disposition. EU‐RMP, EU‐reference medicinal product (adalimumab); PK, pharmacokinetic; US‐RP, US‐reference product (adalimumab)
Figure 2
Figure 2
Mean serum concentration–time profiles (on semi‐logarithmic scale) by treatment following a single subcutaneous injection of 40 mg MSB11022, US‐RP and EU‐RMP. Data are presented as means. EU‐RMP, EU‐reference medicinal product (adalimumab); US‐RP, US‐reference product (adalimumab). EU‐RMP, MSB11022, US‐RP
Figure 3
Figure 3
Mean serum concentration–time profiles (on semi‐logarithmic scale) following a single subcutaneous injection of 40 mg MSB11022, US‐RP, and EU‐RMP according to ADA status for (A) MSB11022, (B) US‐RP, and (C) EU‐RMP. Data are presented as means. ADA, anti‐drug antibody; EU‐RMP, EU‐reference medicinal product (adalimumab); US‐RP, US‐reference product (adalimumab). ADA negative, ADA positive

References

    1. den Broeder A, van de Putte L, Rau R, Schattenkirchner M, Van Riel P, Sander O, et al. A single dose, placebo‐controlled study of the fully human anti‐tumor necrosis factor‐α antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 2002; 29: 2288–98.
    1. Humira (adalimumab) injection, for subcutaneous use. North Chicago, IL: AbbVie Inc., September 2015. [online]. (last accessed 11 December 2015).
    1. SPC . Humira pre‐filled pen, pre‐filled syringe and vial. Maidenhead, UK: Abbvie Ltd, November 2015. [online]. Available at (last accessed 11 December 2015).
    1. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long‐term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013; 72: 517–24.
    1. Benucci M, Li Gobbi F, Meacci F, Manfredi M, Infantino M, Severino M, et al. Antidrug antibodies against TNF‐blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins. Biologics 2015; 9: 7–12.
    1. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti‐adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921–6.
    1. FDA Guidance for Industry Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), April 2015. [online]. Available at (last accessed 11 December 2015).
    1. European Medicines Agency Guideline on similar biological medicinal products containing biotechnology‐derived proteins as active substance: quality issues. London, UK: European Medicines Agency, May 2012. [online]. Available at (last accessed 11 December 2015).
    1. Magnenat L, Palmese A, Fremaux C, D'Amici F, Terlizzese M, Rossi M, et al Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira® . mAbs 2016; Manuscript submitted.
    1. van Schouwenburg PA, van de Stadt LA, de Jong RN, van Buren EE, Kruithof S, de Groot E, et al. Adalimumab elicits a restricted anti‐idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis 2013; 72: 104–9.
    1. van Schouwenburg PA, Kruithof S, Votsmeier C, van Schie K, Hart MH, de Jong RN, et al. Functional analysis of the anti‐adalimumab response using patient‐derived monoclonal antibodies. J Biol Chem 2014; 289: 34482–8.
    1. Thomas SS. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta‐analysis. BioDrugs 2015; 29: 241–58.
    1. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117: 244–79.
    1. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF‐blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005; 34: 819–36.
    1. Keystone EC. Does anti‐tumor necrosis factor‐α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis? A review of long‐term data. J Rheumatol 2011; 38: 1552–62.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel